Table 4.
Univariate and multivariate analyses of the prognostic risk factors for progression-free survival in PTCL
| Variable | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| ECOG (0–1 vs 2–4) | 1.32 (1.02–4.32) | 0.071 | ||
| Ann Arbor stage (I–II vs III–IV) | 1.48 (0.58–3.64) | 0.233 | ||
| B symptoms (absent vs present) | 2.72 (1.63–6.42) | 0.045 | 1.46 (0.68–2.89) | 0.472 |
| β2-MG (normal vs elevated) | 1.29 (0.71–3.87) | 0.592 | ||
| LDH (normal vs elevated) | 0.78 (0.43–3.20) | 0.134 | ||
| IPI (1–2 vs 3–5) | 2.94 (1.52–5.61) | 0.032 | 3.01 (0.98–5.61) | 0.017 |
| CCI (0–1 vs ≥2) | 2.39 (0.54–3.72) | 0.016 | 2.99 (1.14–4.58) | 0.008 |
| Therapeutic evaluation (CR/PR vs SD/PD) | 2.69 (0.35–6.27) | 0.187 | ||
Abbreviations: PTCL, peripheral T-cell lymphoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; β2-MG, β-microglobulin; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CCI, Charlson Comorbidity Index Score.